Guru Sonpavde: ESMO24 bladder cancer highlight HRQoL outcomes from CheckMate 901 trial

Guru Sonpavde shared a post on LinkedIn:

“ESMO24 bladder cancer highlight: Health-related quality of life (HRQoL) outcomes from the Phase III CheckMate 901 Phase III trial of nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin in cisplatin-eligible patients with metastatic urothelial cancer (UC) – no detrimental impact of nivolumab combined with gemcitabine-cisplatin, further supporting its use in this setting – Pleased to participate in this trial and comment from AdventHealth Central Florida Institute on Video Journal of Oncology (VJOncology)”

Proceed to the video attached to the post.
Source: Guru Sonpavde/LinkedIn

Guru Sonpavde is the Oncology and Phase I Clinical Trials Director at AdventHealth Central Florida and the Chair of Bladder Cancer Research. He is also a Professor of Medicine at the University of Central Florida.

His primary focus is drug development, leading innovative clinical trials on novel immunotherapies and targeted therapies for genitourinary cancers, especially bladder cancer, along with prostate, kidney, penile, and testicular cancers.